Quality control of the proteins associated with neurodegenerative diseases
Xuechao Gao,
Hongyu Hu,
Xuechao Gao
State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences, Shanghai 200031, China
Search for more papers by this authorCorresponding Author
Hongyu Hu
State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences, Shanghai 200031, China
*Corresponding author: Tel, 86-21-54921121; Fax, 86-21-54921011; E-mail, [email protected]Search for more papers by this authorXuechao Gao,
Hongyu Hu,
Xuechao Gao
State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences, Shanghai 200031, China
Search for more papers by this authorCorresponding Author
Hongyu Hu
State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, the Chinese Academy of Sciences, Shanghai 200031, China
*Corresponding author: Tel, 86-21-54921121; Fax, 86-21-54921011; E-mail, [email protected]Search for more papers by this authorThis work was supported by a grant from the National Basic Research Program of China (2006CB910305)
Abstract
Most neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease and other polyglutamine diseases are associated with degeneration and death of specific neuronal populations due to misfolding or aggregation of certain proteins. These aggregates often contain ubiquitin that is the signal for proteolysis by the ubiquitin-proteasome system, and chaperone proteins that are involved in the assistance of protein folding. Here we review the role of protein quality control systems in the pathogenesis of neurodegenerative diseases, and aim to learn more from the cooperation between molecular chaperones and ubiquitin-proteasome system responding to cellular protein aggregates, in order to find molecular targets for therapeutic intervention.
References
- 1 Ardley HC, Robinson PA, The role of ubiquitin-protein ligases in neurodegenerative disease. Neurodegener Dis 2004, 1: 71–87.
- 2 Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004, 15: 95–105.
- 3 Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 2004, 11: 1215–1222.
- 4 Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295: 1852–1858.
- 5 Esser C, Alberti S, Höhfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 2004, 1695: 171–188.
- 6 Haslbeck M. sHsps and their role in the chaperone network. Cell Mol Life Sci 2002, 59: 1649–1657.
- 7 Goswami A, Dikshit P, Mishra A, Mulherkar S, Nukina N, Jana NR. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun 2006, 342: 184–190.
- 8 Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci 1999, 19: 10338–10347.
- 9 McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002, 16: 2136–2148.
- 10 Fonte V, Kapulkin V, Taft A, Fluet A, Friedman D, Link CD. Interaction of intracellular β amyloid peptide with chaperone proteins. Proc Natl Acad Sci USA 2002, 99: 9439–9444.
- 11 Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29: 15–32.
- 12 Barral JM, Broadley SA, Schaffar G, Hartl FU. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 2004, 15: 17–29.
- 13 Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 2000, 275: 8772–8778.
- 14 Luo GR, Chen S, Le WD. Are heat shock proteins therapeutic targets for Parkinson's disease. Int J Biol Sci 2007, 3: 20–26.
- 15 Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of β-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295: 865–868.
- 16 Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001, 2: 169–178.
- 17 Layfield R, Cavey JR, Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003, 2: 343–356.
- 18 Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 1999, 8: 673–682.
- 19 Jana NR, Zemskov EA, Wang Gh, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001, 10: 1049–1059.
- 20 Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 2004, 90: 379–391.
- 21 McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004, 56: 149–162.
- 22 Howard RA, Sharma P, Hajjar C, Caldwell KA, Caldwell GA, Du Breuil R, Moore R et al. Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation. BMC Cell Biol 2007, 8: 32.
- 23 Li J, Pauley AM, Myers RL, Shuang R, Brashler JR, Yan R, Buhl AE et al. SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-β peptide production. J Neurochem 2002, 82: 1540–1548.
- 24 Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392: 605–608.
- 25 Tanaka K, Suzuki T, Hattori N, Mizuno Y Ubiquitin, Proteasome and Parkin. Biochim Biophys Acta 2004, 1695: 235–247.
- 26 Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 2003, 278: 22044–22055.
- 27 Kudo T, Imaizumi K, Hara H. A molecular chaperone inducer as potential therapeutic agent for neurodegenerative disease. Nihon Shinkei Seishin Yakurigaku Zasshi 2007, 27: 63–67.
- 28 Nagano Y, Yamashita H, Takahashi T, Kishida S, Nakamura T, Iseki E, Hattori N et al. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J Biol Chem 2003, 278: 51504–51514.
- 29 Ito T, Niwa J, Hishikawa N, Ishigaki S, Doyu M, Sobue G. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J Biol Chem 2003, 278: 29106–29114.
- 30 Niwa J, Ishigaki S, Hishikawa N, Yamamoto M, Doyu M, Murata S, Tanaka K et al. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem 2002, 277: 36793–36798.
- 31 Davies JE, Sarkar S, Rubinsztein DC. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem 2007, 8 Suppl 1: S2.
- 32 Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 2005, 94: 192–203.
- 33 Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005, 120: 73–84.
- 34 Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005, 6: 11–22.
- 35 Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, Tanaka K, Nukina N. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 2005, 280: 11635–11640.
- 36 Dil Kuazi A, Kito K, Abe Y, Shin RW, Kamitani T, Ueda N. NEDD8 protein is involved in ubiquitinated inclusion bodies. J Pathol 2003, 199: 259–266.
- 37 Petrucelli L, Dawson TM. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 2004, 36: 315–320.
- 38 Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phosphor-and caspase-3-cleaved tau species. J Neurosci 2006, 26: 6985–6996.
- 39 Kalia SK, Lee S, Smith PD, Liu L, Crocker SJ, Thorarinsdottir TE, Glover JR et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 2004, 44: 931–945.
- 40 Fu L, Gao YS, Sztul E. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein. Neurobiol Dis 2005, 20: 656–665.
- 41 Cato AC, Mink S. BAG-1 family of cochaperones in the modulation of nuclear receptor action. J Steroid Biochem Mol Biol 2001, 78: 379–388.
- 42 Lüders J, Demand J, Höhfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem 2000, 275: 4613–4617.
- 43 Alberti S, Demand J, Esser C, Emmerich N, Schild H, Hohfeld J. Ubiquitylation of BAG-1 suggests a novel regulatory mechanism during the sorting of chaperone substrates to the proteasome. J Biol Chem 2002, 277: 45920–45927.
- 44 Westhoff B, Chapple JP, Van Der Spuy J, Höhfeld J, Cheetham ME. HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients to the proteasome. Curr Biol 2005, 15: 1058–1064.
- 45 Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, Mitrophanous K, Chapple JP et al. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther 2007, 15: 1100–1105.
- 46 Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 1998, 94: 73–82.
